USA - engelsk - NLM (National Library of Medicine)

deseret biologicals, inc. - adenosine triphosphate (unii: 8l70q75fxe) (adenosine triphosphate - unii:8l70q75fxe) - adenosine triphosphate 8 [hp_x] in 1 ml

USA - engelsk - NLM (National Library of Medicine)

guna spa - adenosine triphosphate (unii: 8l70q75fxe) (adenosine triphosphate - unii:8l70q75fxe), .alpha.-ketoglutaric acid (unii: 8id597z82x) (.alpha.-ketoglutaric acid - unii:8id597z82x), .alpha.-lipoic acid (unii: 73y7p0k73y) (.alpha.-lipoic acid - unii:73y7p0k73y), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), barium oxalosuccinate (unii: l7a49804zq) (barium cation - unii:v645272hln), beet (unii: n487km8cok) (beet - unii:n487km8cok), cerous oxalate nonahydrate (unii: 0uv74p3r0j) (cerous - adenosine triphosphate 8 [hp_x] in 4 g - adenosintriphosphate    8x    cell metabolism alpha-ketoglutaric acid    6x    detoxification alpha-lipoic ac        6x    detoxification ascorbic acid        4x    cell metabolism barium oxalosuccinate    6x    detoxification beta vulgaris        2x    cell metabolism cerium oxalicum        6x    cell metabolism cis-aconitic acid    6x    cell metabolism coenzyme a        6x    cell metabolism cysteinum        6x    cell metabolism embryo extract        6x    cell metabolism fumaricum acidum    6x    anti-inflammatory ginseng            3x    detoxification glandula suprarenalis    10x    hormonal regulation lacticum acidum        8x    cell metabolism magnesium carbonate    2x    tiredness malic acid        6x    cell metabolism manganum phosphoricum    6x    tiredness

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ceva animal health pty ltd - adenosine triphosphate - unknown - adenosine triphosphate nucleotide active 0.0 - active constituent

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ausrichter pty ltd - adenosine triphosphate; uridine triphosphate - parenteral liquid/solution/suspension - adenosine triphosphate nucleotide active 14.0 mg/ml; uridine triphosphate nucleotide active 2.0 mg/ml - nutrition & metabolism - cat | dog | horse | bitch | castrate | cat - queen | cat - tom | colt | donkey | endurance horse | filly | foal | gelding | high - muscular stimulant

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - adenosine triphosphate - musculoskeletal system - dog | dog - greyhound | horse | bitch | castrate | colt | donkey | endurance horse | filly | foal | gelding | high performance h - intracellular energy production | muscle injury treatment | muscular contraction

USA - engelsk - NLM (National Library of Medicine)

viatrexx bio incorporated - epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh), bos taurus artery (unii: r2m88a4hsi) (bos taurus artery - unii:r2m88a4hsi), sus scrofa artery (unii: 63o327782q) (sus scrofa artery - unii:63o327782q), adenosine triphosphate (unii: 8l70q75fxe) (adenosine triphosphate - unii:8l70q75fxe), adenosine cyclic phosphate (unii: e0399ozs9n) (adenosine cyclic phosphate - unii:e0399ozs9n), centella asiatica (unii: 7m867g6t1u) (centella asiatica - unii:7m867g6t1u), citric acid monohydrate (unii: 2968phw8q - viatrexx-adipose  a sterile, injectable, biodegradable, clear isotonic liquid that is injected into the various layers of the skin, muscles, ligaments, joints, other body tissues or added to an iv, either as a push or into the bag. this product should not be used in patients with a known hypersensitivity to any ingredient found in the formula, porcine products, isotonic saline or benzyl alcohol, or patients with a history of severe allergies. as with all injections, epinephrine injection (1:1,000) must be immediately available should an acute anaphylactoid reaction occur due to any component of the injection. this product contains 1% benzyl alcohol. benzyl alcohol has been reported to be associated with a fatal "gasping syndrome" in premature infants. due to the benzyl alcohol content, this product should not be given to a pregnant woman. this product should not be used in patients with a known hypersensitivity to any ingredient in this formula, porcine products, isotonic saline or benzyl alcohol, or patients

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration). adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. adenosine injection is contraindicated in: - second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning arti

USA - engelsk - NLM (National Library of Medicine)

akorn - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration ). adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. adenosine injection is contraindicated in: - second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker). - known hypersensitivity to adenosine.

USA - engelsk - NLM (National Library of Medicine)

cardinal health - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration ). adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. adenosine injection is contraindicated in:

USA - engelsk - NLM (National Library of Medicine)

general injectables & vaccines, inc - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration ). adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. adenosine injection is contraindicated in: - second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning art